Foundation Fighting Blindness

Foundation Fighting Blindness

The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.

Episodes

April 21, 2026 3 mins
Data monitoring committee recommends proceeding with registration-enabling study for ATSN-201
Listen
Watch
Mark as Played
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) by Foundation Fighting Blindness
Listen
Watch
Mark as Played
Strategic funding extends cash runway through 2029 and advances multiple inherited retinal disease programs
Listen
Watch
Mark as Played
VG801 shows sustained vision improvements through 12 months with favorable safety profile
Listen
Watch
Mark as Played
Potential cell therapy, DSP-3077, gains special regulatory status to support development for inherited retinal disease.
Listen
Watch
Mark as Played
First-of-its-kind small molecule therapy targets protein misfolding at the root of RHO-adRP
Listen
Watch
Mark as Played
First patient shows vision improvements with a good safety profile.
Listen
Watch
Mark as Played
To celebrate episode 100 of Eye on the Cure, host Ben Shaberman features highlights from conversations with some of his previous guests including: Dr. Dean Bok from UCLA, Dr. Michel Michaelides from Moorfields Eye Hospital, actor Ben Mehl, triathlete Michael Stone, and jazz keyboardist Matthew Whitaker. This "Best Of" episode is Ben's final for Eye on the Cure, but the podcast will continue on with a new host. Stay tuned!
Listen
Watch
Mark as Played
Novel neuroprotective approach could benefit RP patients regardless of genetic mutation
Listen
Watch
Mark as Played
Listen to the latest episode of the Blind & Beyond radio show featuring Foundation Fighting Blindness CEO Jason Menzo. Jason discusses the Foundation's mission and the remarkable progress achieved over the past 55 years in advancing diagnostics, treatments, and cures for blinding diseases. He also shares insights into ongoing advocacy efforts on Capitol Hill to preserve critical vision research funding through the FDA and National ...
Listen
Watch
Mark as Played
Dr. Prem Subramanian, of the University of Colorado Sue Anschutz-Rodgers Eye Center and School of Medicine, talks with host Ben Shaberman about thyroid eye disease (TED), a condition that is often misdiagnosed and can cause a range of symptoms including discomfort and vision loss. Dr. Subramanian discusses potential causes, symptoms, and therapeutic approaches. This episode is sponsored by Amgen.
Listen
Watch
Mark as Played
Marking an important milestone for this rare form of retinitis pigmentosa (RP)
Listen
Watch
Mark as Played
Milestone brings hope to patients with rare inherited retinal disease
Listen
Watch
Mark as Played
First patient treated in Part B of ASTRA trial evaluating SB-007.
Listen
Watch
Mark as Played
Josh Steinberg and his father, Jon, talk with host Ben Shaberman about their close-knit family's journey with Josh's vision loss and eventual diagnosis of retinitis pigmentosa, as well as their volunteer leadership roles in driving the Foundation's mission. Jon is Chair of the Foundation's Science Committee and Vice Chair for Science on the Board. Josh is the former Chair of the Strategic Council and also a Board director.
Listen
Watch
Mark as Played
Lindsey Rambo, a special education teaching assistant, mom, and wife, talks to host Ben Shaberman about her journey with Leber congenital amaurosis 5 (LCA5), participation in Opus Genetics' LCA5 gene therapy clinical trial, and her appearance on Good Morning America to tell her story about meaningful vision improvements. 
Listen
Watch
Mark as Played
The company has also fully enrolled the Phase 2/3 VISTA clinical trial for its XLRP gene therapy.
Listen
Watch
Mark as Played
Dr. Deniz Dalkara, a research director at INSERM in France, talks to hose Ben Shaberman about her emerging gene-agnostic, gene therapy designed to restore cone-mediated vision in people with advanced retinitis pigmentosa. Known as SPVN20 and clinically developed by SparingVision, the treatment recently moved into a clinical trial in Europe. Dr. Dakara also discusses her earlier work in retinal gene and optogenetic therapy developme...
Listen
Watch
Mark as Played
Tinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.
Listen
Watch
Mark as Played
The Foundation funded preclinical studies for the approach and launched Opus.
Listen
Watch
Mark as Played

Popular Podcasts

    If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

    Dateline NBC

    Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

    Post Run High

    Post Run High features conversations with high-performing founders, athletes, artists, health and science experts, and leaders about what it really takes to succeed. Through honest, post-movement conversations, guests share how they’ve navigated challenges, built resilience, and used movement as a tool for clarity, discipline, and growth. Each episode explores the mindset behind performance — what keeps people going when things get hard — and offers tangible advice listeners can apply in their everyday lives.

    The Buck Sexton Show

    Buck Sexton breaks down the latest headlines with a fresh and honest perspective! He speaks truth to power, and cuts through the liberal nonsense coming from the mainstream media. Interact with Buck by emailing him at teambuck@iheartmedia.com

    The Interface

    Stop doomscrolling. Start decoding the tech rewiring your week - and your world. The Interface is the BBC's fiercely informed, fast and funny take on how tech is changing everything. Hosted by journalists Tom Germain, Karen Hao, and Nicky Woolf, each episode unpacks week-by-week the unfolding story of how technology is shaping all our futures. No guests. No jargon. Just three sharp voices debating the tech news stories that matter - whether they shook a government, broke the internet, or quietly tipped the balance of power. As TikTok shifts geopolitics, Trump drives digital shockwaves, Elon Musk expands his space-internet empire and AI reroutes the routines of everyday life - the trio ask: what world are the tech titans building for us? And do we want to live in it?

Advertise With Us
Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2026 iHeartMedia, Inc.

  • Help
  • Privacy Policy
  • Terms of Use
  • AdChoicesAd Choices